Overview
Eosinophilic nonallergic rhinitis (ENR) is a chronic inflammatory condition characterized by nasal symptoms such as congestion, sneezing, and rhinorrhea, driven primarily by eosinophil activation rather than allergic triggers. This condition affects individuals who do not exhibit typical allergic sensitivities but experience significant nasal discomfort. ENR is clinically significant due to its impact on quality of life and potential overlap with other respiratory conditions. Understanding and managing ENR is crucial in day-to-day practice to alleviate symptoms effectively and prevent complications, particularly in patients with persistent nasal symptoms unresponsive to standard allergy treatments 17.Pathophysiology
The pathophysiology of eosinophilic nonallergic rhinitis involves a complex interplay of inflammatory mediators and cellular responses. Central to this process is the activation and accumulation of eosinophils in the nasal mucosa. Unlike allergic rhinitis, where immunoglobulin E (IgE) plays a pivotal role, ENR often lacks identifiable allergens but is characterized by heightened sensitivity to non-allergic stimuli such as environmental irritants, infections, or hormonal changes. These stimuli trigger the release of cytokines and chemokines, including IL-5, which promotes eosinophil recruitment and activation. Activated eosinophils then release various pro-inflammatory mediators like eosinophil peroxidase and leukotrins, contributing to mucosal inflammation and symptoms 145. Additionally, adhesion molecules such as ICAM-1 and VCAM-1 are upregulated, facilitating the migration of inflammatory cells into the nasal tissues, further exacerbating the inflammatory cascade 4.Epidemiology
The exact incidence and prevalence of eosinophilic nonallergic rhinitis are not well-defined in large population studies, but it is recognized as a common condition affecting a subset of patients with chronic nasal symptoms. ENR tends to affect adults more frequently than children, with no significant gender predilection noted in most studies. Geographic factors and environmental exposures may influence its prevalence, though specific trends over time are less clear. Patients with a history of asthma, atopy, or other chronic inflammatory conditions may be at higher risk, suggesting potential overlaps in underlying mechanisms 27.Clinical Presentation
Patients with eosinophilic nonallergic rhinitis typically present with chronic nasal symptoms including persistent nasal congestion, sneezing, watery rhinorrhea, and sometimes postnasal drip. These symptoms often occur without the typical seasonal patterns seen in allergic rhinitis. Atypical presentations might include anosmia (loss of smell) and facial pressure. Red-flag features that warrant further investigation include severe or progressive symptoms, significant impact on daily activities, and coexisting respiratory symptoms suggestive of asthma or sinusitis. Accurate diagnosis is crucial to differentiate ENR from allergic rhinitis and other nasal pathologies 7.Diagnosis
The diagnosis of eosinophilic nonallergic rhinitis involves a combination of clinical evaluation and supportive laboratory findings. Key steps include:Specific Criteria and Tests:
Differential Diagnosis:
Management
First-Line Treatment
Second-Line Treatment
Refractory Cases / Specialist Referral
Contraindications:
Complications
Prognosis & Follow-up
The prognosis for eosinophilic nonallergic rhinitis varies; many patients achieve symptom control with appropriate management. Prognostic indicators include the severity of initial symptoms, response to first-line treatments, and presence of comorbid conditions like asthma. Regular follow-up every 3-6 months is recommended to monitor symptom control and adjust therapy as needed. Monitoring parameters include symptom scores, nasal endoscopy findings, and periodic nasal smears to assess eosinophil levels 7.Special Populations
Key Recommendations
References
1 Tan Y, Lim LH. trans-Resveratrol, an extract of red wine, inhibits human eosinophil activation and degranulation. British journal of pharmacology 2008. link 2 Kökoğlu K, Şahin MI. Use of Neutrophil, Eosinophil, Basophil, and Platelet to Lymphocyte Ratio to Predict Patient Satisfaction After Septoplasty Plus Inferior Turbinate Reduction. The Journal of craniofacial surgery 2019. link 3 Ahmadi A, Naderi N, Souri M, Shirkavand F, Nahri-Niknafs B. Synthesis and antinociception activity of new substituted phenothiazines and ethylenediamines as antihistaminic drugs. Drug research 2014. link 4 Kupczyk M, Kupryś I, Danilewicz M, Bocheńska-Marciniak M, Murlewska A, Górski P et al.. Adhesion molecules and their ligands in nasal polyps of aspirin-hypersensitive patients. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 2006. link61048-4) 5 Assanasen P, Naclerio RM. Antiallergic anti-inflammatory effects of H1-antihistamines in humans. Clinical allergy and immunology 2002. link 6 Shizawa T, Inaba K, Yoshida F, Iizuka T, Hijikuro K, Yanoshita R et al.. Mechanisms of non-drowsiness after oral administration of TMK688, a novel antiallergic drug. Arzneimittel-Forschung 1998. link 7 Ciprandi G, Pronzato C, Passalacqua G, Ricca V, Grögen J, Mela GS et al.. Topical azelastine reduces eosinophil activation and intercellular adhesion molecule-1 expression on nasal epithelial cells: an antiallergic activity. The Journal of allergy and clinical immunology 1996. link80196-5) 8 Andri L, Senna GE, Betteli C, Givanni S, Andri G, Scaricabarozzi I et al.. Combined treatment of allergic rhinitis with terfenadine and nimesulide, a non-steroidal antiinflammatory drug. Allergie et immunologie 1992. link